BPC-157 and TB-500 (Thymosin Beta-4) are the two most studied peptides for tissue repair and recovery. They work through distinct but complementary mechanisms — BPC-157 primarily promotes angiogenesis and GI healing, while TB-500 promotes actin polymerization and systemic tissue remodeling. Together they address different phases of the healing cascade.
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from human gastric juice. It promotes angiogenesis via VEGF upregulation, modulates nitric oxide synthesis, and accelerates tendon, ligament, and GI mucosal healing. TB-500 is a synthetic fragment of Thymosin Beta-4 that promotes actin polymerization, reduces inflammation, and enhances cell migration — particularly in muscle, tendon, and cardiac tissue.
Both compounds have extensive preclinical evidence in rodent models. BPC-157 has demonstrated accelerated healing in over 100 animal studies across multiple tissue types. TB-500 has shown efficacy in cardiac repair models and tendon healing. No direct human RCTs exist for either compound alone or in combination, but the mechanistic complementarity is well-documented.
Research protocols typically administer both compounds simultaneously, either by subcutaneous injection or intramuscularly near the injury site. Common dosing in animal studies: BPC-157 at 250–500 mcg/day and TB-500 at 2–2.5 mg twice weekly. Some protocols use a loading phase of higher-frequency dosing followed by a maintenance phase.
Both compounds have favorable preclinical safety profiles with no significant toxicity observed in animal studies. The combination does not appear to produce additive adverse effects. The main consideration is that neither compound has been studied in human clinical trials, so all use is considered research-only.
The combination is popular in recovery research because the two compounds address different aspects of tissue repair. BPC-157 is more targeted to local healing (especially GI and tendon), while TB-500 has more systemic effects. Many research protocols use both for comprehensive recovery support.
BPC-157 primarily promotes angiogenesis and local tissue repair, especially in the GI tract and tendons. TB-500 promotes actin polymerization and systemic tissue remodeling, with particular efficacy in muscle and cardiac tissue. They complement rather than duplicate each other.
The compounds can be mixed in the same syringe for injection, though most research protocols administer them separately to allow independent dosing adjustments. There is no known chemical incompatibility between the two peptides.
Most research protocols run 4–8 weeks for acute injury recovery, with some protocols extending to 12 weeks for chronic conditions. A common approach is to run both compounds for the first 4 weeks, then continue BPC-157 alone for maintenance.
Purgo Labs provides research-grade peptides with independent third-party COAs and >99% purity verification.
Shop Purgo LabsMedical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.